Рatients with diabetes have more complications and higher mortality from COVID-19. This is due to the fact that diabetes impairs the immune response. Hyperglycemia causes a violation of the immune response, which in turn cannot control the spread of pathogenic microorganisms and therefore patients with diabetes are more susceptible to infections. The purpose of the work ₋₋ analysis of bibliometric databases of literature on new developments in diabetes and COVID-19 and focused on clinical recommendations for patients with diabetes infected with COVID-19. The search methods included a literature review of scientific articles that studied diabetes and COVID-19.
According to the results of the analysis of the articles obtained as a result of the search in the PubMed, SCOPUS, Web of Science, MedScape databases, a combination of the terms “diabetes and SARS-CoV-2”, “diabetes and COVID-19”, “pathogenesis of diabetes in case of COVID-19”, "pancreas", "clinical features", "diagnosis", "treatment", "clinical recommendations", we found 32 messages from 2020 to 2022. The main parameters of the study were outpatients and inpatients with diabetes and COVID-19 of middle and elderly age starting from 46 years
and up to 82 years of age in France, China, the USA, Great Britain, in which a nationwide, retrospective, populationbased study was conducted. The following concomitant diseases are included in the main studies: arterial hypertension, cardiovascular diseases, heart failure, chronic kidney disease, chronic obstructive pulmonary disease, myocardial infarction, cerebrovascular diseases. Issues of pathogenetic mechanisms in DM and COVID-19, as well as management of patients with DM and COVID-19 are highlighted.

ABSTRACT
Introduction and aim. Information concerning lactoferrin and interleukin-8 (IL-8) local levels in breast milk are not numerous and requires further research. The aim of this study was to determine the content of lactoferrin and interleukin-8 in the breast milk of patients with lactational mastitis, and to identify new potential markers for assessing the activity of the inflammatory process in the mammary gland. Material and methods. This study analyzed the breast milk of 30 women with lactostasis (group I), 37 women with lactational mastitis (group II) and 30 healthy lactating women (age 26±5 years old). The milk content of lactoferrin and interleukin-8 (IL-8) was determined by enzyme-linked immunosorbent assay. Results. The average value of lactoferrin in breast milk of healthy women was 4.78±0.47 mg/mL, exceeding levels in group I 1.8 times (p<0.05). The level of lactoferrin in group II exceeds the control values 3.1 times (p<0.05). The content of IL-8 in breast milk of women in group I was 7.3 times higher than the control (3.63±0.12 pg/mL, p<0.05). In lactational mastitis, the concentration of IL-8 in breast milk exceeded the group I 13.9 times (p<0.05) and was 1.9 times higher than group I (p<0.05). Conclusion. The analysis has revealed an increase of lactoferrin and IL-8 in breast milk of the test groups, which indicates the activation of non-specific protection.